Still hungry on Mounjaro or Wegovy? Why it happens, and what to do

The 30-second summary

• Some hunger on a GLP-1 is normal, especially on the low starting doses. These medicines reduce appetite; they do not switch it off, and the effect varies from person to person.
• Check what kind of hunger it is. Real hunger, food noise, nausea and low blood sugar can all feel alike, and each has a different answer.
• Most causes are fixable: long gaps between meals, meals light on protein and fibre, the week before your period. If it persists at a stable dose, talk to your prescriber rather than adjusting the dose yourself.

First, is it hunger?

Four different things get called "hungry" on a GLP-1.

• Physical hunger: an empty, growling stomach, several hours after eating.
• Food noise: thinking about food, planning the next snack, craving something specific, without an empty stomach. (See food noise and when food noise comes back.)
• Nausea: a hollow, queasy feeling that can pass for hunger, and often comes after a long gap without food. (See nausea on a GLP-1.)
• Low blood sugar: the NHS lists feeling hungry among its symptoms, alongside sweating, shaking, dizziness and heart palpitations. It is rare in people without diabetes, but more likely if you take insulin or other diabetes medicines such as sulfonylureas. If you do, check your blood sugar if you can, and tell your prescriber.

Once you know which one it is, the reasons below make more sense.

Reason 1: you are on a low or starting dose

Every GLP-1 injection starts low. Wegovy and Ozempic start at 0.25 mg, and Ozempic's prescribing information says plainly that 0.25 mg is not a maintenance dose. Mounjaro starts at 2.5 mg for 4 weeks before the first increase.

The effect grows with the dose. In the SURMOUNT-1 trial of tirzepatide, average weight loss over 72 weeks was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg. Trials of semaglutide measured how much less people ate at a free-choice lunch or across a day, and found large reductions at 1 mg and at 2.4 mg.

So feeling hungry on 0.25 mg or 2.5 mg is not a sign that the medicine does not work for you. It is often a sign that you are on the first step. (See your first week on a GLP-1.)

Reason 2: you have just gone up a dose

Many people expect a dose increase to make them less hungry, and are thrown when the opposite seems to happen. There is no trial data on hunger in the days after a dose increase, so here are the most likely explanations rather than a firm answer.

• Side effects peak around increases. The prescribing information for both Wegovy and Mounjaro says stomach side effects are most common while the dose is being increased. Nausea can pass for hunger.
• Long gaps can backfire. A 2025 joint advisory from four US nutrition and obesity medicine societies notes that less interest in food can lead people to go several hours without eating, which for some leads to rebound cravings for sugary and starchy food once they become overly hungry. If a dose increase put you off food for a couple of days, the hunger that follows may be a response to that.
• Levels take time to settle. The prescribing information says steady levels are reached after about 4 to 5 weeks of weekly semaglutide, and 4 weeks of weekly tirzepatide.

If the hunger lasts beyond the first couple of weeks at the new dose, tell your prescriber.

Reason 3: it is the end of your injection week

Blood levels fall between weekly doses. Semaglutide has a half-life of about a week, and tirzepatide about 5 days, according to their prescribing information, so levels are lowest just before the next injection.

The labels do not chart hunger day by day, so there is no evidence that appetite returns before the next dose. But if you notice it does for you, write down which days, and take that to your prescriber. You can change your injection day, as long as there are at least 3 days between two doses, which may help you line up the harder days with the ones you can plan for. Never add an extra dose. (See what to eat on injection day.)

Reason 4: long gaps and too little food

On a GLP-1 it is easy to skip breakfast, forget lunch and arrive at 4pm ravenous. The joint advisory recommends the opposite pattern: regular, small meals at consistent times, and avoiding long periods without food. When appetite is very low, it suggests setting a reminder to eat.

It is worth saying plainly: eating too little is not the goal. The calculator's appetite ceiling and calorie floor exist because under-eating costs muscle and nutrients, and, as the advisory notes, can come back as cravings.

Reason 5: your meals are light on protein and fibre

What you eat changes how long a meal holds you.

• Protein. A 2020 meta-analysis of 49 short-term trials found that meals higher in protein reduced hunger and increased fullness in the hours after eating. Over the longer term, the same effect was not seen, so the practical lesson is to put protein in every meal, not to rely on one large dose. In an earlier study of 19 people, raising protein from 15% to 30% of calories led them to eat about 441 kcal a day less when they could eat as much as they liked.
• Fibre. A 2011 systematic review found that thicker, more viscous types of fibre reduced appetite more often than others, although the effects on how much people ate and weighed were small.

So a breakfast of toast and jam is likely to hold you for less time than eggs, or Greek yoghurt with oats. Put protein first on the plate. (See protein on a GLP-1 and fibre on a GLP-1.)

Reason 6: the week before your period

A 2025 meta-analysis of 15 datasets, covering 330 women, found that energy intake was higher in the luteal phase, the roughly two weeks between ovulation and a period, by an average of about 168 kcal a day. These women were not on GLP-1 medicines, and the authors noted inconsistencies between studies, but the pattern is a familiar one.

If your hunger comes and goes with your cycle, plan for it: more protein and fibre in those weeks, and meals you are happy to eat more of. (See the menstrual cycle and GLP-1 medicines.)

Reason 7: the medicine may be doing less for you

People respond differently, and some respond less. Both Wegovy's and Mounjaro's prescribing information say that if someone has not lost at least 5% of their starting weight after about 6 months, whether to continue should be reviewed. That is a conversation for your prescriber, and it does not mean you have done anything wrong. (See the GLP-1 plateau.)

What to do, in order

1. Work out which kind of hunger it is. Physical hunger, food noise, nausea or possible low blood sugar.
2. Look at the gaps. Eat something with protein every 3 to 4 hours rather than holding out.
3. Build meals around protein, then fibre. Eggs, yoghurt, cottage cheese, fish, chicken, tofu, beans, oats.
4. Note the pattern. Days after a dose increase, the end of the injection week, the week before your period.
5. Talk to your prescriber if it persists at a stable dose, comes with weight regain, or comes with shaking, sweating or dizziness. Never increase your dose yourself.

What to do with this

Hunger is easier to manage when you know what you are aiming for. The calculator works out your calorie target, your protein floor and an estimate of how much you are likely to manage at your dose, so you can plan meals that hold you, not just meals that fit.

Get your numbers

Sources

1. Mounjaro KwikPen solution for injection in pre-filled pen: Summary of Product Characteristics. electronic medicines compendium. emc
2. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen: Summary of Product Characteristics. electronic medicines compendium. emc
3. Ozempic 0.25 mg solution for injection in pre-filled pen: Summary of Product Characteristics. electronic medicines compendium. emc
4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022. PubMed
5. Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017. PubMed
6. Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021. PubMed
7. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars 2025. PubMed
8. Kohanmoo A, et al. Effect of short- and long-term protein consumption on appetite and appetite-regulating gastrointestinal hormones, a systematic review and meta-analysis of randomized controlled trials. Physiol Behav 2020. PubMed
9. Weigle DS, et al. A high-protein diet induces sustained reductions in appetite, ad libitum caloric intake, and body weight despite compensatory changes in diurnal plasma leptin and ghrelin concentrations. Am J Clin Nutr 2005. PubMed
10. Wanders AJ, et al. Effects of dietary fibre on subjective appetite, energy intake and body weight: a systematic review of randomized controlled trials. Obes Rev 2011. PubMed
11. Tucker JAL, et al. The Effect of the Menstrual Cycle on Energy Intake: A Systematic Review and Meta-analysis. Nutr Rev 2025. PubMed
12. NHS. Low blood sugar (hypoglycaemia). nhs.uk
13. NHS. Semaglutide. nhs.uk

Medical disclaimer: Articles in the foodose research library are educational, not medical advice. Never change your dose without talking to your prescriber. See our full medical disclaimer.